Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05705024 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

A Phase 2 study of Corneal Ulcer, sponsored by University of Illinois at Chicago.

Recruiting
Registry status
Phase 2
Development phase
38
Enrollment target
4
Study locations

NCT05705024 is a Phase 2 study of Corneal Ulcer that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 38 participants. The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05705024, a Phase 2 study of Corneal Ulcer, is actively recruiting participants, sponsored by University of Illinois at Chicago.

RECRUITING
Registry status
Phase 2
Development phase
38 participants
Enrollment target
4
Study locations

Study Summary

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.

Conditions Studied

Interventions

  • BIOLOGICAL Mesenchymal Stromal Cells
  • OTHER Control Solution

Study Locations (4)

Illinois

  • Department of Ophthalmology and Visual Sciences - Chicago

Maryland

  • University of Maryland at Baltimore - Baltimore

Massachusetts

  • Mass Eye and Ear Infirmary - Boston

Pennsylvania

  • University of Pennsylvania, Scheie Eye Institute - Philadelphia

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2023-09-29
Est. Completion 2026-09-28
Phase Phase 2

Sponsor

University of Illinois at Chicago

430 total trials

What the Registry Record Tells You About NCT05705024

The ClinicalTrials.gov registry entry for NCT05705024 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Corneal Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Mesenchymal Stromal Cells is the first listed.

NCT05705024 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05705024 about?

NCT05705024 is a clinical study titled "Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells". The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0...

What is the current status of trial NCT05705024?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2023-09-29. Estimated completion is 2026-09-28.

What conditions does trial NCT05705024 study?

This clinical trial studies the following conditions: Corneal Ulcer.

What interventions are being tested in trial NCT05705024?

The interventions under investigation include: Mesenchymal Stromal Cells (BIOLOGICAL), Control Solution (OTHER).

Who is sponsoring clinical trial NCT05705024?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05705024 being conducted?

This trial has 4 study locations across Illinois, Maryland, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Corneal Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.